Akers Biosciences and Premas Biotech have reported positive proof-of-concept data from animal studies of their PRAK-03202 vaccine candidate against Covid-19.

A four-week test in mice met its primary endpoints of safety and immune response, said the companies.

The vaccine candidate was well-tolerated and safe in the animals, with an encouraging immune response.

During the preclinical study, 50 mice across ten cohorts received 5μg, 10μg and 20μg of the vaccine candidate, found to be generally well-tolerated and safe at all doses, without any adverse events.

The companies added that the candidate was safe at higher doses and produced an immune response against the S, E and M SARS-CoV-2 antigens. It induced neutralising antibody titers levels in all the dose cohorts.

Following three doses, all mice groups reported binding antibody levels similar to convalescent patients’ levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Premas Biotech co-founder and managing director Prabuddha Kundu said: “We are happy to report that the vaccine candidate study in mice has gone on well, and the results are positive and encouraging.

“We have engaged with the regulatory authorities in India and are working towards the next steps under their guidance.”

Premas intends to characterise the vaccine candidate’s immune response in the near term. The company is also planning more safety and later stage animal studies to support a potential investigational new drug (IND) application in the US.

Premas is also working with authorities and the regulator in India, while both companies are communicating with regulators in the US.

Akers Biosciences executive chairman Christopher Schreiber said: “We are very encouraged by the immune response and safety milestones met in this study organised with our partner, Premas.

“We are currently moving towards enhanced dialogue with regulatory bodies in both India and the US and look forward to communicating updates with our investors in the near term.”

The companies partnered in March when Akers in-licensed a Covid-19 vaccine candidate developed by Premas.